| Objective:With the failure of immunotherapy in epithelial ovarian cancer,this study aimed at utilizing tumor database to find potential targets of immunotherapy,to find prognostic biomarkers,and to improve the response rate of immunotherapy,thereby individualizing the treatment plan.Methods:Firstly,the study observed the genomic mutation analysis of CXCL13 and SNRPD1 by c Bio Portal database,and predicted the target mi RNA by Target scan database.In Linked Omics database,the co-expression gene was predicted by Spearman test and the function and pathway enrichment analysis was carried out based on GSEA method.The protein-protein interaction network was analyzed through String database,and the relationship between genes and immune cell infiltration was analyzed through TIMER database,so as to explore the mechanism deeply.Secondly,in order to study the differential genes expression and clinical significance,the data of CXCL13 and SNRPD1 m RNA in patients with ovarian serous cystadenocarcinoma and normal clinical tissues were collected from TCGA and GTEx database.The correlation between its expression and clinical stages or other clinical characteristics by chi-square test was researched.COX univariate and multivariate analysis were used to analyze the effects of CXCL13 and SNRPD1 m RNA expression and other clinical information on survival of OV.The Kaplan-Meier survival curve of CXCL13 and SNRPD1 gene expression was calculated,P<0.05 was considered statistically significant difference.Results:1.It is speculated that mi R-186 is the target mi RNA of CXCL13,and the expression of CXCL13 is correlated with CXCL9（P<0.05）;mi R-4733 is the target mi RNA of SNRPD1,and the expression of SNRPD1 is correlated with PSMG2（P<0.05）by Target scan and Linked Omics database.2.Through PPI,GO and KEGG enrichment analysis,it was found that CXCL13 may be involved in T cell regulation,NK cell-mediated cytotoxicity and NF-κB signal pathway.CXCL13 protein interacted with CXCL9,CXCL10 and CXCL11,and they were highly expressed and significantly correlated with prognosis in OV.3.Through PPI,GO and KEGG enrichment analysis,it was found that SNRPD1 interacted with Sn RNP family,LSM3 and PRPF proteins,and may participat in the process of m RNA splicing,gene replication（cell cycle）,transcription and translation.4.Using TIMER tumor immune database,it was illustrated that the expression of CXCL13 was closely related to the tumor purity of ovarian serous cystadenocarcinoma and the infiltration level of immune-related cells.CXCL13 should play an important role in the infiltration of B cells,macrophages（M1）and CD8+T cells（P<0.05）.There was no significant correlation between SNRPD1 and immune cell infiltration（P>0.05）.5.The m RNA expression levels of CXCL13 and SNRPD1 in 426 ovarian serous cystadenocarcinoma tissues compared with 88 normal ovarian tissues through the GEPIA database.It was demonstrated that CXCL13 and SNRPD1 were highly expressed in OV（P<0.05）.6.It was analyzed that CXCL13 and SNRPD1 m RNA expressions were correlated with lymphatic infiltration as well as DSS and CXCL13 expression was correlated with clinical stages and unilateral/bilateral tumor by Chi-square test.Cox univariate and multivariate analysis found that CXCL13 and SNRPD1 were independent prognostic factors（P<0.05）.7.The K-M survival curves showed that the expression of CXCL13 and SNRPD1 was significantly correlated with the prognosis of ovarian serous cystadenocarcinoma patients（P<0.05）,while low expression was associated with poor prognosis of patients.Conclusion:1.The expression of CXCL13 and SNRPD1 in ovarian serous cystadenocarcinoma is higher than that in normal ovarian tissue.The expression of CXCL13 and SNRPD1 is related to overall survival,and low expression is independent predictors of poor prognosis.2.CXCL13 is mainly involved in tumor immune process,related to CD8+T cell and macrophage infiltration,while SNRPD1 gene is mainly involved in DNA replication and transcription,which is related to cell cycle.3.CXCL13 can effectively screen the population with high response rate of immune checkpoint inhibitors in ovarian serous cystadenocarcinoma and become a new target of synergistic immunotherapy.4.CXCL13 and SNRPD1 can be used as biomarkers to predict the prognosis of ovarian serous cystadenocarcinoma. |
PDF Full Text Request